Medicare could limit who gets new Alzheimer’s drug

(By Lauren Jensik for Becker’s Hospital Review)

Medicare members could face barriers to accessing Biogen’s new Alzheimer’s drug, Aduhelm, due to the treatment’s high cost.  Read the article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org